Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

A Study of Anal Cancer Development in HIV Infected People

NCT00107679 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to compare the development of abnormal cell growth or cancer in the anal region of individuals who are receiving one of two different anti-HIV treatment strategies.

Study Locations (13)

California

  • LA Gay & Lesbian Community Service Ctr., Lamba Med. Group CRS — Los Angeles
  • Castro-Mission Health Ctr. CRS — San Francisco

Colorado

  • Univ. of Colorado Health Science Ctr. CRS — Denver
  • Eastside Family Health Ctr. CRS — Denver

Oregon

  • Kaiser Immune Deficiency Clinic of Portland CRS — Portland
  • Oregon Health & Sciences Univ. Internal Medicine (L-475) CRS — Portland

District of Columbia

  • Washington DC VAMC, Washington Regional AIDS Program, Infectious Diseases CRS — Washington D.C.

Florida

  • Univ. of Florida, Div. of Infectious Diseases CRS — Jacksonville

Massachusetts

  • CRI-Boston CRS — Boston

Michigan

  • Henry Ford Hosp. CRS — Detroit

New York

  • Harlem Hospital Ctr./Columbia University CRS (Gordin CTU) — New York

Trial Details

FieldValue
Enrollment Target 560 participants
Start Date 2005-02
Est. Completion 2006-03

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00107679

The ClinicalTrials.gov registry entry for NCT00107679 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 560 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00107679 reports 13 study locations spanning 10 distinct geographic areas — top geographies include California, Colorado, Oregon. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00107679 about?

NCT00107679 is a clinical study titled "A Study of Anal Cancer Development in HIV Infected People". The purpose of this study is to compare the development of abnormal cell growth or cancer in the anal region of individuals who are receiving one of two different anti-HIV treatment strategies.

What is the current status of trial NCT00107679?

This trial is currently completed. The enrollment target is 560 participants. The study started on 2005-02. Estimated completion is 2006-03.

What conditions does trial NCT00107679 study?

This clinical trial studies the following conditions: HIV Infections, Anus Neoplasms. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT00107679?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00107679 being conducted?

This trial has 13 study locations across California, Colorado, District of Columbia, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial